Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) – Drugs In Development, 2024 report and make more profitable business decisions.
Gorlin syndrome, also known as basal cell nevous syndrome, is a condition that affects many areas of the body and increases the risk of developing various cancerous and noncancerous tumors. Symptoms include arrhythmia, medulloblastoma, ovarian fibromas, depressions in the skin, large head size and skeletal abnormalities involving the spine, ribs, or skull. Treatment includes surgery, radiotherapy, and chemotherapy.
The Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) drugs in development market research report provide comprehensive information on the therapeutics under development for Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 8 molecules, with 8 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Activate Therapeutics LLCBristol-Myers Squibb Co
Genentech USA Inc
Kintara Therapeutics Inc
Mayne Pharma Group Ltd
Palvella Therapeutics LLC
Sol-Gel Technologies Ltd
Table of Contents
Table
Figures
Frequently asked questions